Vaccine safety - Achieving the proper balance

JAMA

Volumn 294, Issue 21, 2005, Pages 2763-2765

  Neuzil, Kathleen M ^a,c   Griffin, Marie R ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE;

ACUTE RESPIRATORY TRACT DISEASE; ANAPHYLAXIS; DEATH; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDITORIAL; HEALTH PRACTITIONER; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MORBIDITY; PRIORITY JOURNAL; UNITED STATES; VACCINATION REACTION;

EID: 28844447901     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.21.2763     Document Type: Editorial

References (14)

1. Centers for Disease Control and Prevention. Severe morbidity and mortality associated with influenza in children and young adults-Michigan, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:837-840.
2. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-8):1-40.
3. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004;113:585-593.
4. Neuzil KM, Mellen BG, Wright PF. The impact of influenza on hospitalizations, outpatient visits, and antibiotic prescriptions in children. N Engl J Med. 2000;342:225-231.
5. Centers for Disease Control and Prevention. Tiered use of inactivated influenza vaccine in the event of a vaccine shortage. MMWR Morb Mortal Wkly Rep. 2005;54:749-750.
6. Belshe RB, Gruber WC, Mendelman P, et al. Efficacy of vaccination with live, attenuated, cold-adapted trivalent intranasal influenza vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136:168-175.
7. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Events Reporting System (VAERS)-United States 1991-2001. MMWR Surveill Summ. 2003;52:1-28.
8. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA. 2005;294:2720-2725.
9. Talbot TR, Crocker DD, Peters J, et al. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccine in adults. Infect Control Hosp Epidemiol. 2005;26:494-500.
10. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind, placebocontrolled trial of the safety, transmissibility and phenotypic stability of a live, attenuated, cold adapted influenza virus vaccine (CAIV-T) in children attending day care. Paper presented at: The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Ill. Abstract G-450.
11. Cha TA, Kao Z, Zhao J, et al. Genotypic stability of cold-adapted influenza vaccine in an efficacy clinical trial. J Clin Microbiol. 2000;38:839-845.
12. King JC Jr, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding and immunogenicity of influenza virus vaccine, trivalent, types A & B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis. 2000;181:725-728.
13. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J. 2004;23:138-144.
14. Piedra PA, Gaglani MJ, Riggs M, et al. Live-attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005;116:e397-e407.